Nuvation Bio Inc. 8-K

What Happened

• Nuvation Bio Inc. (NUVB) filed an 8-K on May 27, 2026 reporting the results of its 2026 Annual Meeting of Stockholders. Holders of 290,931,796 shares were present in person or by proxy (289,931,796 Class A and 1,000,000 Class B), representing 83.6% of Class A and 100% of Class B outstanding and entitled to vote as of the March 25, 2026 record date.
• Two Class A directors — Robert B. Bazemore, Jr. and Robert Mashal, M.D. — and one Class B director — Kim Blickenstaff — were elected to serve until the 2029 annual meeting (or until their successors are qualified). KPMG LLP was ratified as the company’s independent registered public accounting firm for fiscal 2026. Stockholders also approved, on an advisory basis, the compensation of the company’s named executive officers (say‑on‑pay).

Key Details

• Director election votes (Class A):
  • Robert B. Bazemore, Jr.: For 197,674,280; Withheld 37,655,082; Broker non‑vote 55,602,434.
  • Robert Mashal, M.D.: For 216,772,840; Withheld 18,556,522; Broker non‑vote 55,602,434.
  • Class B director Kim Blickenstaff: For 1,000,000; Withheld 0.
• Auditor ratification (KPMG LLP) for fiscal year ending Dec 31, 2026: For 290,273,104; Against 413,176; Abstain 245,516.
• Advisory vote on executive compensation (say‑on‑pay): For 230,050,644; Against 4,950,024; Abstain 328,694; Broker non‑vote 55,602,434.

Why It Matters

• The re‑election of the named directors sets the board composition through the 2029 annual meeting, giving investors clarity on governance leadership.
• Ratification of KPMG as auditor confirms the company’s external auditor for fiscal 2026, an important element for financial reporting and audit continuity.
• The advisory approval of executive compensation indicates investor support (by votes cast) for the company’s pay practices as disclosed in the proxy statement. Broker non‑votes (55.6M) affected some tallies, which is relevant when assessing the level of broad shareholder engagement on certain items.